idaho falls ear, nose, and throat specialists
thyroid & parathyroid disorders- click here for thyroid disorders
The parathyroid glands are uniquely charged with control of calcium homeostasis (equilibrium) through the production of parathyroid hormone (PTH) which is active at the level of the bones, kidneys, and gastrointestinal tract. Disorders involving the parathyroid gland may include benign or inherited conditions of overfunction–hyperparathyroidism–and rare malignant conditions of overfunction—parathyroid cancer. Hypoparathyroidism, or low parathyroid activity, may occur through physician or treatment-induced injury, or, rarely, as an autoimmune-related condition.
Hyperparathyroidism results from the overactivity of one or more of the parathyroid glands which generate increased amounts of parathyroid hormone (PTH). There are several types of hyperparathyroidism, influencing the diagnostic evaluation and the recommended surgical treatment.
Sporadic Primary Hyperparathyroidism: Each year, 100,000 new cases of sporadic primary hyperparathyroidism are diagnosed in the United States, affecting 0.2% to 0.5% of the population. Women are more commonly affected than men and the incidence of the disease increases with age. Most cases (85%) are the result of a single parathyroid gland malfunction caused by the development of a benign tumor, known as an adenoma.
In approximately 15% of hyperparathyroid cases, two or more glands grow into adenomas (tumors) resulting in a condition called parathyroid hyperplasia. This disorder is often marked by an increased level of calcium in the blood (hypercalcemia) following an operation for what was thought to be a single adenoma. Hyperplasia can occur sporadically or by a genetic abnormality in Multiple Endocrine Neoplasia (MEN) 1 and 2. MEN-1 influences the development of tumors in the pituitary gland and pancreas, whereas MEN-2 influences the thyroid and adrenal glands.
This form of hyperparathyroidism typically occurs in patients who have kidney failure or kidney disease. A form of parathyroid hyperplasia, it stems from/on blood-calcium levels.
Caused by known kidney failure or disease, this disorder is characterized by high calcium levels when hyperplastic parathyroid glands begin to function autonomously.
Depending on the type, hyperparathyroidism may cause virtually no symptoms or it may create severe, life-threatening symptoms particularly when associated with very high calcium levels. Patients may experience one or more of the following symptoms:
- Loss of appetite
- Frequent urination
- Muscle weakness
- Joint pain
- Nausea and vomiting
- Dyspepsia (indigestion)
- Abdominal pain
- Trouble with concentration and/or memory loss
Complications can also arise in the form of associated conditions such as:Kidney stones
- Unintentional weight loss
- Pancreatitis or ulcers
- Blood in the urine
Because many patients are entirely asymptomatic, diagnosis often occurs after the detection of mildly elevated calcium levels during routine blood work. In order to diagnose associated conditions/complications, however, bone densitometry (bone mineral density) tests, as well as monitoring urinary excretion of calcium and creatinine and kidney X-ray are used.
Treatment options for hyperparathyroidism include surgery and medical therapy. Surgery to remove the affected gland(s) most often cures this disorder. When performed by an experienced surgeon, the operation is successful in over 95% of cases and serious surgical complications are uncommon. Surgery is recommended for patients who have overt symptoms or complications and for asymptomatic patients who meet the following criteria:
- Young age (50 years or less)
- Significant decrease in bone mineral density
- At least 30% decrease in kidney function
- The presence of significant calcium levels in the urine
- A calcium level 1.0 mg/dl above the upper limit of normal
Medical therapy may be appropriate for patients with mild hypercalcemia (excess of calcium) with no associated symptoms or complications. Possible medical treatments include estrogen-receptor modulators for postmenopausal women and bisphosphates to prevent bone loss. If surgery is not performed, careful monitoring of blood calcium levels, kidney function, and bone densitometry must be enforced in order to prevent the progression or the disorder.